Cardiff Oncology 552953CD1 Bond

CRDF Stock  USD 3.27  0.43  11.62%   
Cardiff Oncology holds a debt-to-equity ratio of 0.024. . Cardiff Oncology's financial risk is the risk to Cardiff Oncology stockholders that is caused by an increase in debt.

Asset vs Debt

Equity vs Debt

Cardiff Oncology's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Cardiff Oncology's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Cardiff Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Cardiff Oncology's stakeholders.
For most companies, including Cardiff Oncology, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Cardiff Oncology, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Cardiff Oncology's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
  
Check out the analysis of Cardiff Oncology Fundamentals Over Time.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.
View Bond Profile
Given the importance of Cardiff Oncology's capital structure, the first step in the capital decision process is for the management of Cardiff Oncology to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Cardiff Oncology to issue bonds at a reasonable cost.
Popular NameCardiff Oncology MGM Resorts International
SpecializationPharmaceuticals, Biotechnology & Life Sciences
Equity ISIN CodeUS14147L1089
Bond Issue ISIN CodeUS552953CD18
S&P Rating
Others
Maturity Date1st of September 2026
Issuance Date19th of August 2016
Coupon4.625 %
View All Cardiff Oncology Outstanding Bonds

Cardiff Oncology Outstanding Bond Obligations

Understaning Cardiff Oncology Use of Financial Leverage

Cardiff Oncology's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Cardiff Oncology's total debt position, including all outstanding debt obligations, and compares it with Cardiff Oncology's equity. Financial leverage can amplify the potential profits to Cardiff Oncology's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Cardiff Oncology is unable to cover its debt costs.
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Cardiff Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.
Please read more on our technical analysis page.

Currently Active Assets on Macroaxis

When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:
Check out the analysis of Cardiff Oncology Fundamentals Over Time.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.